Calibrating Human Immunity in the Context of Advanced Microbial Evolution and Self-Camouflaging
Authors: Carp Theodor-Nicolae 
Published: December 2024

The concept of microbial evolution has become progressively intriguing for the immunological side of scientific research, as the ongoing evolutionary battle between microbial agents and animal immunity, which comprises a set of single-nucleotide polymorphisms (SNPs) for both the microbes and the host organisms by means of adaptation to environmental changes, has started including weak points within the innate host immunity as well. Namely, it was discovered only later in the contemporary era that microbial agents tend to use a method of silencing first and second immune lines as an escaping route toward an abundant distribution of the microbial load without a significant restriction from the host organism at the time. Furthermore, it was discovered that the innate immune system displays visible traits of specificity and memory, and also that the adaptive immune system does contain areas of non-specificity as well, which makes it possible for vaccine-based research efforts to bring a wider inclusion of innate, first-line and second-line immune elements into the overall equation of development and possibly rollout as well, perhaps by using such elements as potential immunising agents as well. Additionally, it is possible for central elements of the adaptive immune system to be treated with major elements of the innate immune system by means of improving their overall function and long-term efficacy against pathogenic agents of potential health concern. Such a context may be adapted for a potential delay or even prophylaxis of HIV-induced AIDS, through the treatment and possibly inoculation of adaptive lymphocytes with a low dose of Type I and Type III Interferon glycoproteins, perhaps in combination with a low dose of protollin, which is a pharmaceutical substance that potentially displays immunostimulatory and immunomodulatory effects that are similar to the ones displayed by Type I and Type III Interferons. The present context may also be adapted for a potential delay in the onset of specific proteinopathies, such as Alzheimer’s Disease and possibly Retinitis Pigmentosa as well. An overall approach as such may help the research area of vaccine development undergo potential updates that will potentially help save even more lives worldwide, through the development and application of a scientific concept known as “United Immune System”, as it may be important to transform the smaller and less direct “road” between natural and adaptive immunity into a broader and more direct “highway” between the two immune departments. Such a clinical application may be combined with potential fresh updates into pathogen-derived vaccine development, by using inactivated or completely lysed microbial genomes either lacking the genes encoding microbial proteins with suppressive effects against the host innate immune system, or containing such genes as the only activated microbial genes, to stimulate the host immune system to build novel evolutionary pathways and particularly adapt to changes in the microbial genome that affect the innate immune system, such as the expression of Type I and Type III Interferons.